Enhertu approved in the US as first tumour-agnostic HER2-directed therapy
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
Aurigene.AI is an end-to-end solution for small molecule drug discovery
This acquisition enables MTD to open new, strategic markets
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
This partnership combines Tata Elxsi's design and technology expertise along with Dräger's expertise in medical and safety technology
Under the arrangement, Dr. Reddy's will have exclusive rights to promote and distribute Sanofi's vaccine brands Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel and Avaxim 80U
Subscribe To Our Newsletter & Stay Updated